Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Jeffrey Gates’ Gates Capital Management Bought $NTK

Jeffrey Gates’ Gates Capital Management filed SEC 13G on November 25th for its 12% passive stake in Nortek Inc (NTK). This is a brand-new position in Gates Capital Management. Now Gates Capital Management has 1.83 million shares in NTK. NTK started to trade on NASDAQ Global Market on November 15th after the company reported $1.4 million profit in the third quarter. Now the stock is priced at $21.

nortek

According to the firm’s official profile, Gates Capital Management is “a leading alternative asset manager providing investment advice to institutional clients and high net worth individuals globally.  The firm currently manages investment partnerships with a staff of ten.  Gates Capital was founded in 1996, is headquartered in New York, and is an SEC registered investment adviser.”

Nortek Inc. is a leading diversified global manufacturer of innovative, branded residential and commercial ventilation, HVAC and technology products. The company primarily operates Residential Ventilation Products segment, Technology Products segment, Residential Air Conditioning and Heating Products segment, Commercial Air Conditioning and Heating Products segment. The company was founded in 1967 and is based in Providence, Rhode Island.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!